GlassScriptPhysician profile
Michael C Tigar
NPI 1790759876
$1,360.89
in general payments reported to CMS, 2019-2025
22 companies · $559 in 2025
The $559 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.63 · 2023: $337 · 2024: $450 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $347.79 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $269.91 | 2023-2025 | Qelbree, Qelbree |
| Abbott Laboratories | $110.85 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $90.63 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $62.95 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $61.64 | 2024-2025 | |
| Abbvie INC. | $58.29 | 2023 | Ubrelvy, Qulipta |
| Ironshore Pharmaceuticals INC. | $38.91 | 2024 | |
| Verrica Pharmaceuticals INC. | $36.34 | 2024 | Ycanth |
| Medtronic, INC. | $30.61 | 2025 | Inceptiv |
| Inspire Medical Systems, INC. | $30.06 | 2023 | Inspire |
| Neurelis, INC. | $26.89 | 2025 | Valtoco |
| Daiichi Sankyo INC. | $23.92 | 2024 | Injectafer |
| Optinose US, INC. | $23.65 | 2025 | |
| Collegium Pharmaceutical, INC. | $22.73 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $20.78 | 2025 | |
| Cipher Pharmaceuticals US LLC | $19.61 | 2025 | Natroba, Spinosad |
| Merck Sharp & Dohme LLC | $18.52 | 2025 | Gardasil 9, Proquad, M-M-R II |
| Seqirus USA INC | $18.02 | 2025 | Fluad, Flucelvax |
| Xeris Pharmaceuticals, INC. | $16.83 | 2023 | Gvoke Hypopen |
| Sage Therapeutics, LLC | $16.24 | 2024 | |
| Boston Scientific Corporation | $15.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tigar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.